Unlocking The Combination to Target Evasive Kidney Cancers
Roughly one in four people with kidney cancer have a type that does not respond to targeted therapy drugs, leaving no proven treatment options for those whose tumors have started to spread.
“It’s very much an unmet need,” says George Thomas, M.D., whose research team has discovered a potential way to stop these cancers by combining two different targeted agents.
Read the full article here: Blogs.ohsu.edu/Cancer Translated
The journal Cell Reports Medicine published the findings online today